7 Questions to Ask a Regenerative Medicine Provider in Tennessee

Regenerative medicine has become increasingly visible to patients looking for options for persistent joint, spine, and musculoskeletal concerns.



But if you are considering one of these therapies, the most important decision may not be whether to have a procedure.

It may be which questions you ask before agreeing to one.

Regenerative medicine is a broad category. Products, procedures, evidence, regulatory status, manufacturing processes, and appropriate uses can differ substantially.

Tennessee also established a new framework in 2026 allowing qualifying physicians to perform certain stem cell and regenerative medicine therapies that have not been approved by the U.S. Food and Drug Administration when statutory requirements are met. That framework includes requirements involving product documentation, informed consent, advertising disclosure, and adverse-event reporting.

Those changes make informed patient conversations especially important.

Here are seven questions worth asking any regenerative medicine provider before making a treatment decision.

1. What Is My Actual Diagnosis?

Before discussing a regenerative procedure, you should understand what is causing your symptoms.

“Knee pain” is not a diagnosis.

Neither is “back pain,” “shoulder pain,” or “joint pain.”

Similar symptoms can result from very different underlying problems. Knee pain, for example, may involve osteoarthritis, a meniscal injury, tendon dysfunction, ligament damage, referred pain, altered biomechanics, or several factors occurring together.

Those distinctions can affect which treatment options make sense.

Ask your provider: What do you believe is causing my symptoms, and what information supports that diagnosis?

A thoughtful evaluation may consider your medical history, physical examination, previous treatment, medications, available imaging, functional limitations, and other clinical factors.

A procedure should follow the diagnosis, not replace it.

2. What Exactly Are You Planning to Use?

“Regenerative medicine” is not the name of a single product.

Patients may hear terms such as:

• stem cells;
• cellular therapy;
• Wharton’s jelly;
• exosomes;
• biologics;
• platelet-rich plasma, or PRP; and
• orthobiologics.

These terms can refer to very different products and procedures.

If a provider recommends treatment, ask specifically: What is the product or procedure called, what does it contain, and where does it come from?

Do not be afraid to ask for the actual product name and manufacturer.

The Tennessee framework itself recognizes distinctions between different regenerative products and establishes different documentation requirements depending on what is being used. For certain products covered by the law, that includes lot-specific sterility documentation and a certificate of analysis.

Patients should know what is being put into their bodies.

3. Is This Specific Therapy FDA-Approved for My Condition?

This deserves a direct answer.

The FDA regulates regenerative medicine products, including many stem cell and exosome products. The agency currently states that regenerative medicine therapies of the types commonly marketed to consumers have not been approved for orthopedic conditions such as osteoarthritis, tendonitis, disc disease, back pain, knee pain, neck pain, shoulder pain, or hip pain.

That does not mean every product described as regenerative medicine has the same regulatory status.

It does mean patients should ask the question precisely:

Is this particular product or therapy FDA-approved for the condition you are proposing to treat?

Be careful with similar-sounding phrases such as:

“FDA registered.”

“Made in an FDA-registered facility.”

“FDA listed.”

“Available under Tennessee law.”

None of those statements, by itself, means the FDA has approved that therapy for your diagnosis.

Tennessee law and FDA approval are separate regulatory questions. Tennessee’s 2026 law expressly addresses certain therapies that have not been approved by the FDA.

4. What Product Testing and Documentation Are Available?

This question becomes especially important when a biological product is involved.

Ask: What documentation exists for the specific product and lot being used?

Tennessee’s new framework establishes product-related requirements for therapies covered by the statute. For qualifying regenerative medicine products, this can include a lot-specific sterility report, certificate of analysis, and manufacturer documentation appropriate to the type of product involved. The statute specifically references information such as cell viability and surface-marker reports for cellular products, viscosity reporting for Wharton’s jelly, and particle counts for exosome-based regenerative products.

A provider should be able to explain what documentation is available and what that documentation actually tells you.

It is also important to understand what it does not establish.

A certificate of analysis, sterility report, manufacturer accreditation, or FDA facility registration is not the same thing as FDA approval of the therapy for your medical condition.

5. What Evidence Supports Using This Therapy for Someone Like Me?

Availability is not the same as evidence.

Regenerative medicine is an active area of research, and the strength of the evidence can vary greatly depending on the exact product, procedure, diagnosis, and patient population.

Ask: What research supports using this specific therapy for my particular condition?

Then go one step further: How closely do the patients in that research resemble me?

A study involving one type of product, diagnosis, or procedure does not necessarily establish the effectiveness of a different product for a different condition.

Be cautious when evidence is described only with vague statements such as:

“Studies show it works.”

“Patients get great results.”

“It helps the body heal itself.”

A good medical conversation should be more specific.

The FDA has warned consumers about broad claims surrounding unapproved regenerative medicine products and notes that some have been marketed for conditions without adequate evidence of safety or effectiveness.

6. What Are the Risks, Alternatives, and Realistic Expectations?

Every medical treatment deserves a risk-benefit discussion.

Ask your provider:

What are the known and potential risks?

What outcome would you consider realistic for someone with my condition?

What alternatives should I consider before deciding?

Those alternatives might include rehabilitation, medication, chiropractic or other conservative care, established injections or procedures, surgical evaluation, watchful waiting, or another approach depending on the diagnosis.

Patients should also be wary of guarantees.

No responsible provider can promise that a regenerative procedure will eliminate pain, regenerate cartilage, prevent surgery, or produce the same outcome for every patient.

The FDA has received reports of adverse outcomes associated with unapproved regenerative medicine products, including infections, unwanted inflammatory or immune responses, and other complications.

Tennessee’s framework also requires physicians practicing under the law to report adverse events associated with qualifying therapies to their licensing authority, with additional reporting requirements applying in certain allogeneic cases.

A transparent provider should be willing to discuss both potential benefits and uncertainty.

7. What Happens After the Procedure?

The conversation should not end when the procedure does.

Ask:

How will you determine whether treatment has helped?

When will I be reevaluated?

What symptoms should prompt me to call the office?

Who do I contact if I experience an unexpected reaction?

What other care might be part of my recovery or treatment plan?

Follow-up matters because outcomes are not always immediate or straightforward.

It also helps distinguish a medically managed treatment plan from a one-time transaction.

The FDA encourages patients and healthcare professionals to report adverse events related to products marketed as regenerative medicine through its MedWatch program.

One More Question: Are You Comfortable With the Answers?

The seven questions above provide useful information.

But there is another factor worth considering: Does the provider answer them clearly?

Patients should not need a medical degree to understand what is being proposed.

Be cautious if straightforward questions about a product, FDA status, evidence, manufacturing source, risks, or alternatives are answered with vague marketing language.

Statements such as “cutting-edge,” “natural,” “FDA registered,” or “regenerative” do not replace a clear medical explanation.

You should understand:

• what is being recommended;
• why it is being recommended;
• what is known about it;
• what remains uncertain;
• what the alternatives are; and
• what happens next.

If you do not understand the answer, keep asking.

What Tennessee’s New Regenerative Medicine Law Means for Patients

Tennessee enacted HB 2246, now Public Chapter 1016, in 2026. The law permits qualifying physicians to perform certain stem cell and regenerative medicine therapies that have not received FDA approval when the therapy falls within the physician’s scope of practice and the law’s requirements are satisfied.

Among other things, the framework addresses product sourcing and documentation, written informed consent, advertising disclosures, and adverse-event reporting.

That creates a new state framework.

It does not make an otherwise unapproved therapy FDA-approved.

For a deeper explanation, read: Tennessee’s New Regenerative Medicine Law: What Patients Should Know About HB 2246 & Is Regenerative Medicine FDA-Approved? Understanding FDA Approval vs. Tennessee Law

How True Wellness Approaches Regenerative Medicine

At True Wellness Integrated Medicine, we believe regenerative medicine should begin with an evaluation, not a sales pitch.

Our approach is to first understand the patient’s symptoms, diagnosis, medical history, previous treatment, goals, and overall clinical picture.

If an emerging therapy deserves consideration, patients should understand what is being proposed, its regulatory status, available evidence, potential risks and benefits, reasonable alternatives, and what to expect afterward.

And sometimes the appropriate recommendation may be another treatment entirely.

The goal is not to make every patient a regenerative medicine patient.

The goal is to help each patient make a more informed decision about the options available to them.

Considering Your Options?

If you have been dealing with an ongoing joint, spine, or musculoskeletal concern, start by understanding the problem.

A medical evaluation can help clarify the diagnosis, review what you have already tried, and identify which treatment options may warrant consideration based on your individual circumstances.

Tennessee-Required Notice

THIS NOTICE MUST BE PROVIDED TO YOU UNDER TENNESSEE LAW. This physician performs one (1) or more stem cell or regenerative medicine therapies that have not yet been approved by the United States food and drug administration. You are encouraged to consult with your primary care provider before undergoing any stem cell or regenerative medicine therapy.

This article is provided for general educational purposes and does not constitute medical or legal advice. Individual treatment decisions should be made following an appropriate medical evaluation.